Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Maria Gomez

Maria Gomez

Professor

Maria Gomez

Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol

Author

  • Kim Gooding
  • Marlena Maziarz
  • Anna-Maria Dutius Andersson
  • Anna Zetterqvist
  • Maria F Gomez
  • Steven Sourbron

Summary, in English

BACKGROUND: Diabetic kidney disease (DKD) remains one of the leading causes of premature death in diabetes. DKD is classified on albuminuria and reduced kidney function (estimated glomerular filtration rate (eGFR)) but these have modest value for predicting future renal status. There is an unmet need for biomarkers that can be used in clinical settings which also improve prediction of renal decline on top of routinely available data, particularly in the early stages. The iBEAt study of the BEAt-DKD project aims to determine whether renal imaging biomarkers (magnetic resonance imaging (MRI) and ultrasound (US)) provide insight into the pathogenesis and heterogeneity of DKD (primary aim) and whether they have potential as prognostic biomarkers in DKD (secondary aim). METHODS: iBEAt is a prospective multi-centre observational cohort study recruiting 500 patients with type 2 diabetes (T2D) and eGFR ≥30 ml/min/1.73m2. At baseline, blood and urine will be collected, clinical examinations will be performed, and medical history will be obtained. These assessments will be repeated annually for 3 years. At baseline each participant will also undergo quantitative renal MRI and US with central processing of MRI images. Biological samples will be stored in a central laboratory for biomarker and validation studies, and data in a central data depository. Data analysis will explore the potential associations between imaging biomarkers and renal function, and whether the imaging biomarkers improve the prediction of DKD progression. Ancillary substudies will: (1) validate imaging biomarkers against renal histopathology; (2) validate MRI based renal blood flow measurements against H2O15 positron-emission tomography (PET); (3) validate methods for (semi-)automated processing of renal MRI; (4) examine longitudinal changes in imaging biomarkers; (5) examine whether glycocalyx and microvascular measures are associated with imaging biomarkers and eGFR decline; (6) explore whether the findings in T2D can be extrapolated to type 1 diabetes. DISCUSSION: iBEAt is the largest DKD imaging study to date and will provide valuable insights into the progression and heterogeneity of DKD. The results may contribute to a more personalised approach to DKD management in patients with T2D. TRIAL REGISTRATION: Clinicaltrials.gov ( NCT03716401 ).

Department/s

  • EXODIAB: Excellence in Diabetes Research in Sweden
  • Diabetic Complications

Publishing year

2020

Language

English

Publication/Series

BMC Nephrology

Volume

21

Issue

1

Document type

Journal article

Publisher

BioMed Central (BMC)

Topic

  • Endocrinology and Diabetes
  • Urology and Nephrology

Keywords

  • Albuminuria
  • Biomarkers
  • Chronic kidney disease stages 1–3
  • Diabetic kidney disease
  • Magnetic resonance imaging
  • Progression
  • Prospective cohort
  • Renal decline
  • Type 2 diabetes
  • Ultrasound

Status

Published

Research group

  • Diabetic Complications

ISBN/ISSN/Other

  • ISSN: 1471-2369